Legend Biotech Corporation (NASDAQ: LEGN) has priced an underwritten public offering of 7,700,000 American Depositary Shares (ADSs) at $29.35 per ADS, according to a press release issued June 17, 2026.

Each ADS represents two ordinary shares of the Bridgewater, N.J.-based company. The gross proceeds from the offering are expected to be approximately $226 million before deducting underwriting discounts, commissions, and other offering expenses.

Legend Biotech has also granted underwriters a 30-day option to purchase up to an additional 1,155,000 ADSs at the public offering price, less underwriting discounts and commissions. Proceeds from any exercise of that option are not included in the $226 million figure.

The offering is expected to close on June 23, 2026, subject to customary closing conditions. All ADSs in the offering are being sold by Legend Biotech.

Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank Securities are serving as joint book-running managers for the offering.

The ADSs are being offered pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission.